Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

A Global Perspective on Biomarkers in Gastrointestinal Cancer
  • CME

Credits Available
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: August 16, 2021 Expiration: August 15, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Merck Sharp & Dohme Corp.
David H. Ilson, MD, PhD
John L. Marshall, MD
Eric Van Cutsem, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the available data and expert recommendations to determine which biomarkers should be assessed in your patients with gastrointestinal malignancies
  • Plan therapeutic strategies for patients with gastrointestinal malignancies based on predictive biomarker assessment
  • Evaluate the clinical validity, utility, and differences among single biomarker companion diagnostics and available comprehensive genomic testing platforms using next-generation sequencing
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in gastrointestinal malignancies for patient counsel and potential enrollment

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

David H. Ilson, MD, PhD

Professor of Medicine
Weill Cornell Medical College
Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

David H. Ilson, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, and Taiho.
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees from Bayer, Caris, Indivumed, Daiichi Sankyo, and Taiho; salary from Indivumed; and fees for non-CME services from Bayer, Daiichi Sankyo, Merck, Pfizer, and Taiho.
Eric Van Cutsem, MD, PhD

Professor of Medicine
University of Leuven
Head, Digestive Oncology Unit
University Hospital Gasthuisberg
Leuven, Belgium

Eric Van Cutsem, MD, PhD, has disclosed that he has received consulting fees from AbbVie, Array, Astellas, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, GlaxoSmithKline, Halozyme, Helsinn, Incyte, Ipsen, Janssen Research, Lilly, Merck Sharp & Dohme, Merck KGaA, Mirati, Novartis, Pierre Fabre, Roche, Seattle Genetics, Servier, Sirtex, Terumo, Taiho, TRIGR, and Zymeworks and received funds for research support (paid to his institution) from Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, and Servier.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan Topping, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for global physicians and other healthcare professionals who treat and manage patients with gastrointestinal cancers.

Goal

The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to optimally integrate current and emerging biomarkers to guide treatment decisions for patients with select GI malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 16, 2021, through August 15, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

A Global Perspective on Biomarkers in Gastrointestinal Cancer
  • CME

Loading...
In this interactive webcast, experts discuss how the latest data on the use of biomarker-driven treatments for patients with gastrointestinal cancers affects their clinical practice.
David H. Ilson, MD, PhD
John L. Marshall, MD
Eric Van Cutsem, MD, PhD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Released: August 16, 2021 Expiration: August 15, 2022

Related Content

In this slideset from Clinical Care Options (CCO), experts discuss their thoughts on dosing of regorafenib and TAS-102 for colorectal cancer (CRC).

Kanwal Raghav, MD person default Rachel Riechelmann, MD, PhD Released: October 21, 2021

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

Expert commentary on the use of PARP inhibitors in the treatment of pancreatic cancer, from Clinical Care Options (CCO)

Dirk Arnold, MD, PhD Released: October 5, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Daiichi Sankyo, Inc.
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue